CN102334032B - 预测对基于铂的治疗的反应性 - Google Patents

预测对基于铂的治疗的反应性 Download PDF

Info

Publication number
CN102334032B
CN102334032B CN201080007960.0A CN201080007960A CN102334032B CN 102334032 B CN102334032 B CN 102334032B CN 201080007960 A CN201080007960 A CN 201080007960A CN 102334032 B CN102334032 B CN 102334032B
Authority
CN
China
Prior art keywords
rbm3
sample
cancer
protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080007960.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102334032A (zh
Inventor
K·杰斯特罗姆
J·埃伯哈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlas Antibodies AB
Original Assignee
Atlas Antibodies AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/SE2009/000091 external-priority patent/WO2009102261A1/en
Priority claimed from EP09158084A external-priority patent/EP2241889A1/en
Priority claimed from EP09167847A external-priority patent/EP2293070A1/en
Application filed by Atlas Antibodies AB filed Critical Atlas Antibodies AB
Publication of CN102334032A publication Critical patent/CN102334032A/zh
Application granted granted Critical
Publication of CN102334032B publication Critical patent/CN102334032B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201080007960.0A 2009-02-16 2010-02-16 预测对基于铂的治疗的反应性 Expired - Fee Related CN102334032B (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
PCT/SE2009/000091 WO2009102261A1 (en) 2008-02-15 2009-02-16 Rbm3 as a marker for breast cancer prognosis
SEPCT/SE2009/000091 2009-02-16
US16996309P 2009-04-16 2009-04-16
EP09158084.5 2009-04-16
US61/169,963 2009-04-16
EP09158084A EP2241889A1 (en) 2009-04-16 2009-04-16 RBM3 protein in colorectal cancer prognostics
US23376909P 2009-08-13 2009-08-13
US61/233,769 2009-08-13
EP09167847.4 2009-08-13
EP09167847A EP2293070A1 (en) 2009-08-13 2009-08-13 Means and methods for ovarian cancer prognosis
EPPCT/EP2009/067419 2009-12-17
PCT/EP2009/067419 WO2010091763A1 (en) 2009-02-16 2009-12-17 Rbm3 as a marker for malignant melanoma prognosis
PCT/EP2010/051941 WO2010092190A2 (en) 2009-02-16 2010-02-16 Prediction of response to platinum-based therapy

Publications (2)

Publication Number Publication Date
CN102334032A CN102334032A (zh) 2012-01-25
CN102334032B true CN102334032B (zh) 2015-01-28

Family

ID=41718882

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080007960.0A Expired - Fee Related CN102334032B (zh) 2009-02-16 2010-02-16 预测对基于铂的治疗的反应性

Country Status (8)

Country Link
US (3) US8632984B2 (enExample)
EP (4) EP2396657B1 (enExample)
JP (3) JP5611986B2 (enExample)
CN (1) CN102334032B (enExample)
AU (4) AU2009339802B2 (enExample)
CA (3) CA2749349A1 (enExample)
DK (2) DK2396660T3 (enExample)
WO (5) WO2010091763A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2396657B1 (en) * 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis
EP2524928A1 (en) 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer
EP2630498A4 (en) * 2010-10-22 2014-10-01 Vermillion Inc PROGNOSTIC BIOMARKERS IN PATIENTS WITH OVARIAN CANCER
US20120288480A1 (en) * 2011-02-22 2012-11-15 Taipei Medical University Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications
EP2573566A1 (en) 2011-09-20 2013-03-27 Atlas Antibodies AB RBM3 in prostate cancer prognostics
CN102590185B (zh) * 2012-01-11 2013-12-25 东南大学 以适体为识别单元的胶体晶体凝胶非标记可视化检测方法
WO2016004387A1 (en) * 2014-07-02 2016-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene expression signature for cancer prognosis
EP3023791A1 (en) * 2014-11-21 2016-05-25 Atlas Antibodies AB Predicting the responsiveness to gemcitabine treatment
CN106611094B (zh) * 2015-10-15 2021-08-06 北京寻因生物科技有限公司 基于肠道微生物菌群预测及干预化疗药物毒副反应的系统
CN113373151B (zh) * 2021-06-30 2022-05-03 华中科技大学同济医学院附属协和医院 环状RNAhsa_circ_0008399的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084485A2 (en) * 2006-01-13 2007-07-26 Battelle Memorial Institute Markers for assessing copd-related diseases
WO2009102261A1 (en) * 2008-02-15 2009-08-20 Atlas Antibodies Ab Rbm3 as a marker for breast cancer prognosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
GB9917027D0 (en) 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
WO2006071896A2 (en) * 2004-12-23 2006-07-06 The Hong Kong University Of Science And Technology Epitope-based sars vaccine
EP1934867A2 (en) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP1862803A1 (en) * 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer
US7902166B2 (en) 2008-04-03 2011-03-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
EP2396657B1 (en) * 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis
EP2524928A1 (en) * 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084485A2 (en) * 2006-01-13 2007-07-26 Battelle Memorial Institute Markers for assessing copd-related diseases
WO2009102261A1 (en) * 2008-02-15 2009-08-20 Atlas Antibodies Ab Rbm3 as a marker for breast cancer prognosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Decreased Expression of Mouse Rbm3,a Cold-Shock Protein, in Sertoli Cells of Cryptorchid Testis;Shozo Danno et al;《American Journal of Pathology》;20000531;第156卷(第5期);第1685-1692页 *
Down-Regulating Cold Shock Protein Genes Impairs Cancer Cell Survival and Enhances Chemosensitivity;Yu Zeng et al;《Journal of Cellular Biochemistry》;20090310;第107卷(第1期);第181页右栏第2段至183页右栏第1段，附图2、3、5、6，摘要 *
Yu Zeng et al.Down-Regulating Cold Shock Protein Genes Impairs Cancer Cell Survival and Enhances Chemosensitivity.《Journal of Cellular Biochemistry》.2009,第107卷(第1期), *

Also Published As

Publication number Publication date
WO2010092190A2 (en) 2010-08-19
WO2010092184A1 (en) 2010-08-19
EP2396660A2 (en) 2011-12-21
EP2396657B1 (en) 2013-11-13
HK1166371A1 (en) 2012-10-26
US8747910B2 (en) 2014-06-10
EP2396346B1 (en) 2013-04-03
JP2012518164A (ja) 2012-08-09
JP5767116B2 (ja) 2015-08-19
WO2010092187A1 (en) 2010-08-19
JP2012518162A (ja) 2012-08-09
WO2010091763A1 (en) 2010-08-19
AU2010212764B2 (en) 2014-07-17
CA2749349A1 (en) 2010-08-19
AU2010212769B2 (en) 2014-07-17
US20120034317A1 (en) 2012-02-09
AU2009339802B2 (en) 2014-07-24
EP2396657A1 (en) 2011-12-21
AU2010212772B2 (en) 2014-07-17
JP5611986B2 (ja) 2014-10-22
CA2749392A1 (en) 2010-08-19
WO2010092190A3 (en) 2010-11-04
AU2009339802A1 (en) 2011-07-28
US8632984B2 (en) 2014-01-21
CN102334032A (zh) 2012-01-25
AU2010212772A1 (en) 2011-07-28
WO2010092182A1 (en) 2010-08-19
JP5669757B2 (ja) 2015-02-18
EP2396659A1 (en) 2011-12-21
JP2012518163A (ja) 2012-08-09
DK2396660T3 (da) 2013-10-28
DK2396659T3 (da) 2013-03-04
US20120058202A1 (en) 2012-03-08
AU2010212769A1 (en) 2011-07-28
AU2010212764A1 (en) 2011-07-28
EP2396346A1 (en) 2011-12-21
CA2749350A1 (en) 2010-08-19
EP2396660B1 (en) 2013-07-24
US20120269764A1 (en) 2012-10-25
EP2396659B1 (en) 2012-11-21
AU2010212769C1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
CN102334032B (zh) 预测对基于铂的治疗的反应性
AU2010311540B9 (en) PODXL protein in colorectal cancer
US8728739B2 (en) RBM3 in colorectal cancer prognostics
EP2293070A1 (en) Means and methods for ovarian cancer prognosis
WO2014161980A1 (en) Asrgl1 in endometrial cancer
EP2241889A1 (en) RBM3 protein in colorectal cancer prognostics
HK1166371B (en) Prediction of response to platinum-based therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1166371

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1166371

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150128

Termination date: 20210216